Y-box binding protein-1 at the crossroads of DNA damage response and tumor immune evasion

JNCI Cancer Spectrum · Published 2026-04-22 · DOI 10.1093/jncics/pkag044

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1093/jncics/pkag044

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Luteinizing hormone-releasing hormone in prostate cancer treatment: from hypothalamic discovery to clinical translation · JNCI Cancer Spectrum · 2026 · Same journal
• Computational identification of salient cancer care topics and themes in oncology social work notes · JNCI Cancer Spectrum · 2026 · Same journal
• Trends in adult exclusive and dual use of combustible and non-combustible tobacco products in the United States · JNCI Cancer Spectrum · 2026 · Same journal
• Sociodemographic trends in prostate cancer: Insights from the all of Us research program · JNCI Cancer Spectrum · 2026 · Same journal
• Feasibility evaluation of a virtual lifestyle intervention for early-stage breast cancer survivors undergoing chemotherapy · JNCI Cancer Spectrum · 2026 · Same journal
• Clinical outcomes in pediatric acute lymphoblastic leukemia using modified BFM-95 protocol: 10-year study in Mexico City · JNCI Cancer Spectrum · 2026 · Same journal
• Emergency cancer diagnosis in older adults: patterns, subgroups, and implications for health-care quality metrics · JNCI Cancer Spectrum · 2026 · Same journal
• Contrastive multimodal deep learning for survival prediction in grade 2/3 gliomas · JNCI Cancer Spectrum · 2026 · Same journal
• Bone and soft tissue sarcoma mortality in 19 811 patients diagnosed in Japan, 2006-2020 · JNCI Cancer Spectrum · 2026 · Same journal
• Migration-adjusted lung cancer burden in China: a population data-based Bayesian spatial modeling approach · JNCI Cancer Spectrum · 2026 · Same journal